1-methyl-3-(pyridin-2-yl)-1H-pyrazole-4-carboxylic acid | 1152510-81-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-methyl-3-(pyridin-2-yl)-1H-pyrazole-4-carboxylic acid
• 英文别名: 1-methyl-3-pyridin-2-ylpyrazole-4-carboxylic acid
• CAS: 1152510-81-0
• 化学式: C₁₀H₉N₃O₂
• 分子量: 203.2
• InChiKey: WQYDINHISJQINO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  68
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• [EN] HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS<br/>[FR] PIPÉRIDINES HALOSUBSTITUÉES EN TANT QUE MODULATEURS DE RÉCEPTEUR DES OREXINES
  申请人：ASTRAZENECA AB

  公开号：WO2017139603A1

  公开（公告）日：2017-08-17

  The present application relates to certain halo-substituted piperidine compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating substance addiction, panic disorder, anxiety, post-traumatic stress disorder, pain, depression, seasonal affective disorder, an eating disorder, or hypertension.

  本申请涉及某些含卤代哌啶化合物、含有它们的药物组合物，以及使用它们的方法，包括用于治疗物质成瘾、恐慌障碍、焦虑、创伤后应激障碍、疼痛、抑郁、季节性情感障碍、进食障碍或高血压的方法。
• Halo-substituted piperidines as orexin receptor modulators
  申请人：AstraZeneca AB

  公开号：US10894789B2

  公开（公告）日：2021-01-19

  The present application relates to certain halo-substituted piperidine compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating substance addiction, panic disorder, anxiety, post-traumatic stress disorder, pain, depression, seasonal affective disorder, an eating disorder, or hypertension.

  本申请涉及某些卤代哌啶化合物、含有这些化合物的药物组合物以及使用这些化合物的方法，包括治疗药物成瘾、恐慌症、焦虑症、创伤后应激障碍、疼痛、抑郁症、季节性情感障碍、饮食失调或高血压的方法。
• HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS
  申请人：Astrazeneca AB

  公开号：EP3414241B1

  公开（公告）日：2022-05-04
• HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS
  申请人：Boehringer Ingelheim International GmbH

  公开号：US20210292301A1

  公开（公告）日：2021-09-23

  Disclosed are heteroaromatic carboxamides of formula (I), wherein Y, R, and Ar are as defined herein, and pharmaceutically acceptable salts thereof. Also disclosed are the use of the compounds of formula (i) for the treatment of diseases which can be influenced by the inhibition of plasma kallikrein.